Novel Therapeutic Effects of Leonurine On Ischemic Stroke: New Mechanisms of BBB Integrity

Figure 7

SCM-198 maintained the BBB integrity via enhancing the expression of HDAC4. The HDAC4 inhibitor Taq (0.2 μM) or vehicle was applied 1 h before until the end of the experiment. (a–f) Western blot images and quantitative analysis suggested inhibition of HDAC4 increased the expression of NOX4 and MMP-9, and treatment with 10 μM SCM-198 reduced the raised levels of NOX4 and MMP-9. Meanwhile, SCM-198 decreased the loss of TJs. The results revealed SCM-198 could protect against the degradation of TJs via improving the expression of HDAC4, F (4, 15) = 13.24, , Figure 7(b); F (4, 13) = 28.16, , Figure 7(c); F (4, 10) = 43.70, , Figure 7(d); F (4, 10) = 27.45, , Figure 7(e); F (4, 10) = 50.05, , Figure 7(f); (g–k) The mRNA levels of NOX4, MMP-9, and TJs were estimated by real-time RT-PCR, F (4, 10) = 8.332, , Figure 7(g); F (4, 10) = 39.14, , Figure 7(h); F (4.10) = 401, , Figure 7(i); F (4.10) = 144.9, , Figure 7(j); F (4.10) = 39.03, , Figure 7(k). Values are expressed as mean ± SEM. ^# versus the control group, versus the OGD group, .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)